THU0684 Prevalence of rheumatic diseases in adult population in spain. episer 2016 study

Abstract

Background Prevalence of rheumatic diseases was first studied in Spain in 2000 EPISER 2000 study1). Sociodemographic and lifestyle changes during the last 16 years and their possible influence in prevalence figures justify a new study. Objectives To estimate the prevalence of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), Sjögren syndrome, symptomatic osteoarthritis (knee, hip, hands, cervical and lumbar spine), fibromyalgia, gout and symptomatic osteoporotic fracture in adult population in Spain. View this table: Methods Population-based multicenter cross-sectional study, with the participation of 78 municipalities in the 17 Spanish autonomous communities. The reference population are adults aged 20 and above residing in Spain. All participants gave their informed consent. CATI system (Computer Assisted Telephone Interview) was used for initial data collection and screening questionnaire. Diagnostic suspicions and diagnosis referred by the participants were studied by rheumatologists in the referral hospital for the selected municipalities. Statistical analysis: the prevalence of the rheumatic diseases were calculated using estimators and their 95% confidence intervals. Weights were calculated in each of the sampling stages in accordance with the probability of selection. The distribution of population in Spain obtained from the National Statistics Institute was taken into account. Results 4916 subjects were included in the study. 4753 completed their participation. Prevalence of rheumatic diseases were the following: The negative predictive value (NPV) of the initial screening questionnaire was 93.8%. The lower NPV corresponded to knee osteoarthritis (95.1%). Conclusions Prevalence of RA, PsA, AS, gout and SLE seems to be higher than previously published in other European countries. Reference [1] Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis2001;60(11):1040–5. Acknowledgements This study was funded by Celgene, Gebro Pharma, MSD, Novartis, Hopira/Pfizer and Sanofi Genzyme. Disclosure of Interest None declared